Polypeptides such as glucagon-like peptide-1 (GLP-1) analogue used to prevent obesity represents a new direction for drug design, but with poor adherence of patients to injectable therapies. Oral ...
ACCP Position Statement: "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists"
Feb. 5, 2025 /PRNewswire/ -- The American College of Clinical Pharmacology ® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor ...
Attribution (BY): Credit must be given to the creator. Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long-acting peptide therapeutics for type 2 diabetes and ...
Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...
BIRMINGHAM, Ala. (WBRC) - Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become popular when used as a weight loss drug. But, ...
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists, or GLP-1.
Share on Pinterest A new study compares the risks and benefits of using GLP-1 medications. Iuliia Burmistrova/Getty Images The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists ...
Of those, over 215,000 had been prescribed a glucagon-like peptide-1 (GLP-1) agonist receptor — the class of drugs that includes Ozempic, Wegovy, Mounjaro, Zepbound, and others — and 1.7 ...
A team of researchers at Queen Mary University of London have discovered how a small change in the vimentin protein can make breast cancer more aggressive. By modifying a specific amino acid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback